Clinical Trials in Atlanta

Showing 5021-5040 of 14,993 trials

Biomarkers for Event-driven PrEP Adherence

NCT04298697

This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for the measurement of anti-retroviral drug concentrations in various body compartment sites. Participants will be involved in the study for up to 24 weeks.

Human Immunodeficiency Virus

Emory University43 participantsStarted Feb 2020

Atlanta, Georgia, United States

COMPLETEDPhase 3< 1 mile

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Methicillin-Resistant Staphylococcus AureusBacterial InfectionsStaphylococcal Skin Infections

AbbVie199 participantsStarted Mar 2017

Mobile, Alabama, United States • Phoenix, Arizona, United States • La Palma, California, United States +81 more locations

Biomarkers for Event-driven PrEP Adherence

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Find Trials by Condition in Atlanta

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

2021 PMT iAge® Intervention Trial by Edifice Health

International Weight Control Registry

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Sildenafil Exercise: Role of PDE5 Inhibition

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

Breast Cancer Index (BCI) Registry

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry